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1. Introduction 
Pancreatic carcinoma is one of the most lethal solid tumors, with particularly high mortality-
to-incidence rates. Indeed, about 278,684 people were diagnosed worldwide of pancreatic 
cancer in 2008, of whom 266,669 dyed from the disease in the same year (Ferlay et al, 2010). 
The greatest impact is observed in developed countries were pancreatic cancer has become 
the fourth leading cause of cancer-related death (Jemal et al, 2010).  
Pancreatic ductal adenocarcinoma represents more than 90% of pancreatic malignancies. 
The majority arise in the head, neck or uncinate process (60-70%), being less commonly 
encountered in the body (5-10%) or tail (10-15%) of the gland (Solcia et al, 1997). Clinical 
presentation is often related to the location of the primary tumor within the gland, 
although many patients often undergo an initial period of nonspecific symptoms such as 
back pain or vague gastrointestinal distress. Jaundice may be a relatively early symptom 
for tumors located in the head or uncinate process of the pancreas. However, left-sided 
pancreatic tumors may remain asymptomatic for long periods of time. Other associated 
disorders include acute pancreatitis or diabetes mellitus, and when they develop in 
patients without risk factors or in conjunction with other associated symptoms such as 
pain, anorexia or weight loss, the possibility of an underlying malignancy should be 
considered. Thromboembolic complications are also very common and are associated 
with a poor prognosis, with an incidence ranging from 17% to 57% (Khorana & Fine, 
2004). Anorexia, weight loss or gastric outlet obstruction generally occur late in the course 
of the disease. Nevertheless, even early symptoms in this tumor are usually indicative of 
advanced disease.  
Clinical features of pancreatic adenocarcinoma translate its extremely high propensity for 
local invasion and distant spread, underscoring the great difficulty to obtain an early 
diagnosis. In fact, more than 70% of patients present with unresectable, locally advanced or 
metastatic disease at the time of diagnosis (Stathis & Moore, 2010), and 70-80% of resected 
tumors will eventually relapse following surgery. Once the tumor has progressed beyond 
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surgical resectability, prognosis is rather poor, with median survival ranging from 6 to 9 
months and 5-year overall survival rates of less than 5% (National Cancer Institute, 2010; 
Jemal et al, 2008).  
In recent years there has been only minimal progress in the systemic treatment of metastatic 
pancreatic cancer. Current standard therapies have a limited impact on the natural history 
of this disease and improvements in systemic therapy are desperately needed in order to 
improve the prognosis of these patients. However, intense translational and clinical research 
has lead to a better and deeper understanding of the complex molecular biology of this 
tumor and shall help improve the development of new more effective drugs in this disease. 
2. Conventional cytotoxic therapy 
2.1 Monotherapy 
Early randomized trials demonstrated that several 5-fluorouracil (5FU)-based combination 
chemotherapy regimens improved survival (hazard ratio [HR] = 0.64; 95%CI, 0.42 to 0.98) 
and quality of life of patients with advanced pancreatic cancer over best supportive care 
(BSC) alone (Sultana et al, 2007). Subsequent studies showed, however, that 5FU-based 
combination therapy did not result in better overall survival compared with 5FU alone (HR 
= 0.94; 95% CI, 0.82 to 1.08). 5FU monotherapy became, consequently, the standard of care 
for pancreatic cancer. Reported response rates widely ranged from 0% to 19% (Evans et al, 
1997), partly due to the lack of standardized criteria to assess response in these early trials, 
with median survival times of 4.2 to 5.5 months (Burris et al, 1997).  
During the 1990s several non-controlled trials suggested some promising activity of a new 
drug in pancreatic cancer, gemcitabine. The pivotal study by Burris et al was responsible for 
the change in practice from 5FU to gemcitabine based on a marginal survival advantage and 
an improvement in clinical benefit response favoring gemcitabine-treated patients. This trial 
enrolled 126 patients with chemotherapy-naïve advanced symptomatic pancreatic cancer 
who were randomly allocated to receive gemcitabine (1000 mg/m2/week x 7 followed by 1 
week of rest, and then weekly x 3 every 4 weeks) or 5-FU (600 mg/m2/week) until disease 
progression, clinical deterioration or unacceptable toxicity (Burris et al, 1997). The primary 
efficacy outcome was clinical benefit response (CBR), a term introduced for the first time in 
this trial, which was a composite of measurements of pain (analgesic consumption and pain 
intensity), Karnofsky performance status and weight. No statistically significant difference 
was found between study arms in terms of objective response (gemcitabine 5.4% vs 5-FU 
0%), but patients in the gemcitabine arm experienced improved CBR (24% vs 5%) and 
overall survival (5.65 months vs 4.41 months, p=0.0025), with 1-year survival rates also 
favoring gemcitabine-treated patients (18% vs 2%).  
Further trials aimed to optimize gemcitabine administration schedule. Gemcitabine 
(difluorodeoxycytidine) is a nucleoside analogue capable of inhibiting ribonucleotide 
reductase to deplete nucleoside pools, and its phosphorylated metabolite is incorporated 
into DNA causing chain termination and inhibition of DNA synthesis, function and repair. 
Phosphorylation of gemcitabine to the monophosphate by deoxycytidine kinase is the rate-
limiting step in the accumulation of the active diphosphate and triphosphate metabolites. 
Some early clinical studies observed the rate of gemcitabine triphosphate accumulation by 
mononuclear cells and leukemia cells was optimized using dose rates of 10 mg/m2/min. 
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Conversely, preclinical data had suggested a dose-response relationship independent of 
infusion duration. In light of these data, a randomized phase II trial conducted in 92 
pancreatic cancer patients was designed to assess the efficacy of two dose-intense schedules 
of gemcitabine: a dose-intense schedule administering gemcitabine as a standard 30-minute 
infusion (2200 mg/2/week) versus gemcitabine administered at a fixed dose rate (FDR) of 
10 mg/m2/min (1500 mg/m2/week 150-minute infusion) (Gelibter et al, 2005; Tempero et 
al, 2003). Patients in the FDR infusion arm experienced increased survival rates (18% vs 2% 
at 2 years, p=.007), consistent with the higher intracellular gemcitabine triphosphate 
concentrations observed in these patients, although at the expense of increased hematologic 
toxicity. However, a confirmatory phase III trial failed to confirm a survival advantage for 
the FDR regimen over the standard administration (Poplin et al, 2009). 
2.2 Combination chemotherapy 
Although the benefit of chemotherapy in patients with advanced pancreatic cancer is well 
established, the magnitude of the effect is rather small, with an absolute improvement of 
survival at 5 years of 3% to 6% (survival rates from 1975-77 to 1999-2005) (Oberstein & Saif, 
2011). Over the past decade, multiple randomized trials have been performed to assess a 
number of gemcitabine-combination chemotherapy regimens in an effort to improve these 
modest results. These have included combinations with 5-FU (Berlin et al, 2002; Riess et al, 
2005), capecitabine (Herrmann et al, 2007; Bernhard et al, 2008; Cunningham et al, 2009), 
cisplatin (Heinemann et al, 2006; Colucci et al, 2002, 2009), oxaliplatin (Louvet et al, 2005; 
Poplin et al, 2009), irinotecan (Rocha et al, 2004; Stathopoulos et al, 2006), exatecan (Abou 
Alfa et al, 2006) and pemetrexed (Oettle et al, 2005a). Individually, although many of these 
studies observed some improvement in terms of response rate and progression free survival 
favoring combination therapy, the great majority failed to demonstrate a survival benefit 
(Table 1). 
The largest and most recent meta-analysis, however, confirm a modest although significant 
benefit in survival for gemcitabine combinations over gemcitabine alone (HR 0.91; 95%CI: 
0.85 to 0.97; p=0.004) in patients with locally advanced or metastatic pancreatic cancer 
(Sultana et al, 2007; Heinemann et al, 2008b). The magnitude of this benefit was remarkably 
greater (HR 0.76; 95%CI: 0.67 to 0.87; p<0.0001) in patients with good performance status 
(representing 38% of all patients included in the meta-analysis). In subgroup analysis, 
platinum compounds (3 trials, 1077 patients; HR 0.85; 95%CI 0.74-0.96) and capecitabine (3 
trials, 935 patients; HR 0.83; 95%CI 0.72-0.96) in combination with gemcitabine consistently 
showed improved survival over single-agent gemcitabine. Insufficient evidence was 
observed, nevertheless, to support combination of gemcitabine with 5FU or irinotecan.  
The rationale for the combined use of gemcitabine and cisplatin is based on the preclinical 
evidence that gemcitabine not only increases cisplatin-induced DNA cross links, but also 
effectively inhibits their repair, and cisplatin, on the other hand, enhances the incorporation 
of gemcitabine triphosphate into DNA. In vitro studies show synergistic cytotoxicity and 
several non-controlled clinical studies suggested improved efficacy. Some early randomized 
studies observed increased response rates and progression free survival for patients treated 
with the cisplatin-gemcitabine combination as compared to those treated with gemcitabine 
alone (Colucci et al, 2002; Heinemann et al, 2006), with a non-significant trend towards a  
longer survival. However, more recent and larger trials have failed to confirm a significant  
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Reference Treatment Number 
of patients 
Response Rate 
(%) 
PFS  
(months) 
OS 
(months) 
Berlin et al 
(2002) 
GEM vs 
GEM+5FU 
327 5.6 vs 6.9 2.2 vs 3.4 
(p=0.022) 
5.4 vs 6.7 
(p=0.09) 
Herrmann 
et al (2007) 
GEM vs 
GEM+ 
CAP 
319 7.8 vs 10 3.9 vs 4.3 
(p=0.103) 
7.2 vs 8.4 
(p=0.234) 
Cunningh
am et al 
(2009) 
GEM vs 
GEM+ 
CAP 
533 12 vs 19 
(p=0.034) 
3.8 vs 5.3 
(p=0.004) 
6.2 vs 7.1 
(p=0.08) 
Colucci et 
al (2002) 
GEM vs 
GEM+CIS 
107 9.2 vs 26.4 
(p=0.02) 
1.8 vs 4.6 
(p=0.048) 
5 vs 7.5 
(p=0.43) 
Colucci et 
al (2010) 
GEM vs 
GEM+CIS 
400 10.1 vs 12.9 
(p=0.37) 
3.9 vs 3.8 
(p=0.80) 
8.3 vs 7.2 
(p=0.38) 
Heineman
n et al 
(2006) 
GEM vs 
GEM+CIS 
195 8.2 vs 10.2 3.1 vs 5.3 
(p=0.053) 
6 vs 7.6 
(p=0.15) 
Louvet et 
al (2005) 
GEM vs 
GEM+OX 
313 17.3 vs 26.8 
(p=0.04) 
3.7 vs 5.8 
(p=0.04) 
7.1 vs 9 
(p=0.13) 
Poplin et al 
(2009) 
GEM vs  
GEM FDR 
GEM+OX 
832 6 vs 10 vs 9 
(p=0.11) 
2.6 vs 3.5 
(p=0.04) vs 2.7 
(p=0.1) 
4.9 vs 6.2 
(p=0.04) 
vs 5.7 
(p=0.22) 
Stathopoul
os et al 
(2006) 
GEM vs 
GEM+IRI 
145 10 vs 15 
(p=0.39) 
2.8 vs 2.9 
(p=0.79) 
6.4 vs 6.5 
(p=0.97) 
Rocha 
Lima et al 
(2004) 
GEM vs 
GEM+IRI 
360 4.4 vs 16.1 
(p<0.001) 
3 vs 3.5 
(p=0.352) 
6.6 vs 6.3 
(p=0.789) 
Oettle et al 
(2005a) 
GEM vs 
GEM+ 
PEM 
565 7.1 vs 14.8 
(p=0.004) 
3.3 vs 3.9 
(p=0.11) 
6.3 vs 6.2 
(p=0.847) 
Abou Alfa 
et al (2006) 
GEM vs 
GEM+EXA 
349 4.6 vs 6.3 3.8 vs 3.7 
(p=0.22) 
6.2 vs 6.7 
(p=0.52) 
5FU, 5-fluoruracil; GEM, gemcitabine; CAPE, capecitabine; CIS, cisplatin; OX, oxaliplatin; IRI, 
irinotecan; EXE, exatecan; PEM, pemetrexed; RR, response rate; PFS, progression free survival; OS, 
overall survival. 
Table 1. Selected phase III trials of gemcitabine-based chemotherapy in advanced pancreatic 
cancer 
impact on overall survival, whereas combination therapy was associated with greater 
hematological toxicity (Colucci et al, 2010). Similar findings have been observed with the 
combination of gemcitabine with oxaliplatin (GEMOX). GEMOX was superior to 
gemcitabine in terms of response rate (26.8% v 17.3%; p=0.04), progression-free survival (5.8 
v 3.7 months; p=0.04), and clinical benefit (38.2% v 26.9%; p=0.03), with a trend for an 
improved survival (9.0 v 7.1 months, p=0.13) (Louvet et al, 2005). Severe toxicities were 
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however more commonly induced by the combination, particularly thrombocytopenia, 
emesis and neurotoxicity. More recently published trials, again, did not confirm these 
benefits for the GEMOX regimen (Poplin et al, 2009). 
Combination of gemcitabine plus capecitabine is the other cytotoxic chemotherapy doublet 
that has shown some advantage over gemcitabine alone. Two recent phase III studies 
consistently demonstrated a gain in terms of progression free survival (PFS) for the 
combination, although the benefit in overall survival (OS) only achieved statistical 
significance in the meta-analysis of these trials (Cunningham et al, 2009; Herrmann et al, 
2007). Cunningham et al randomized 533 patients to receive gemcitabine (1000 mg/m2 in 
30-min infusion weekly x 3 every 4 weeks) plus capecitabine (830 mg/m2/12 hours day 1-21 
every 28 days) versus gemcitabine alone. Combination therapy obtained higher response 
rates (19.1% vs 12.4%, p=0.034) and PFS (5.3 vs 3.8 months; HR 0.78, 95% CI 0.66-0.93, 
p=0.004) and a trend toward better OS of borderline significance (7.1 vs 6.2 months; HR 0.86, 
95% CI 0.72-1.02, p=0.08). Herrmann and colleagues randomized 319 patients to receive 
either gemcitabine (1000 mg/m2 days 1 and 8 every 21 days) plus capecitabine (650 
mg/m2/12 hours days 1-14 every 21 days) or gemcitabine alone (1000 mg/m2 weekly for 7 
weeks and one week off, and then weekly x 3 every 4 weeks). No significant differences 
were observed among study arms in terms of response rate, clinical benefit or quality of life 
(Bernhard et al, 2008), and the primary endpoint of the study, OS, was not reached (8.4 vs 
7.2 months, p=0.234). However, post hoc analysis did show a significant survival advantage 
for the gemcitabine-capecitabine combination in patients with good performance status (10.1 
vs 7.4 months, p=0.004). In both studies toxicity in the combination arm was tolerable, with 
a low incidence of grade 3-4 adverse events, being neutropenia and diarrhea the most 
commonly encountered toxicities. In light of these results, treatment with gemcitabine plus 
capecitabine may be considered in fit patients with advanced pancreatic cancer. 
Other multidrug combinations have also been investigated over the past years in several 
phase II-III trials, including PEFG (cisplatin, epirubicin, gemcitabine and 5-FU) (Reni et al, 
2005), G-FLIP (irinotecan, gemcitabine, 5-FU, leucovorin and cisplatin) (Goel et al, 2007), and 
active schedules in other gastrointestinal cancers such as FOLFOX-6 (oxaliplatin, 5-FU and 
folinic acid) (Ghosn et al, 2007) or FOLFIRI.3 (irinotecan, 5-FU and folinic acid) (Taïeb et al, 
2007). Increased tumor responses and progression free survival have been reported for some 
of these regimens (Reni et al, 2005), although at the expense of a worse toxicity profile with 
no impact on survival. However, the combination of Gemcitabine and nab-paclitaxel, an 
albumin-bound formulation of paclitaxel particles (Celgene, Summit, NJ), deserves special 
mention (Von Hoff et al, 2011).  nab-Paclitaxel has shown antitumor activity in various 
advanced cancer types that overexpress the albumin-binding protein SPARC (secreted 
protein acidic and rich in cysteine), including breast, lung, and melanoma.  Results of the 
phase I/II trial of this combination, with an overall response rate of  48%, a median survival 
of 12.2 months, and a 1-year survival rate of 48% at the MTD are among the highest ever 
reported for a phase II study in patients with advanced pancreatic cancer.  Interestingly, 
SPARC expression in the stroma, but not in the tumor, was correlated with improved 
survival (median survival of 17.8 v 8.1 months for high- vs low- SPARC tumors, 
respectively; P= .0431), suggesting SPARC could be a potential new predictive biomarker of 
nab-paclitaxel activity.  This promising results have prompted the conduction of a large 
international phase III study that is close to complete accrual. Also recently reported, results 
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of the PRODIGE 4/ACCORD 11 trial comparing gemcitabine alone (1000 mg/m2 weekly x 7 
every 8 weeks and then weekly x 3 every 4 weeks) to FOLFIRINOX (oxaliplatin 85 mg/m2, 
irinotecan 180 mg/m2, 5-FU 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as 
a 46-hour continuous infusion; and leucovorin 400 mg/m2; every 2 weeks) demonstrated 
remarkable and significant improvements in response, progression free and overall survival 
rates favoring patients treated with FOLFIRINOX (31% vs. 9%, 6.4 months vs. 3.3 months, 
and 11.1 months vs. 6.8 months, respectively) (Conroy, 2011). These results are somewhat 
surprising, given the known modest activity of each of the individual drugs included in the 
regimen, and shall be confirmed. In addition, the higher toxicity profile of this combination 
limits its widespread use as standard of care in patients with metastatic disease, often frail. 
However, it may be an excellent option for carefully selected patients, particularly those 
with locally advanced borderline resectable disease. Anyhow, this is the first phase III 
randomized trial that has demonstrated a benefit in overall survival of unquestionable 
clinical relevance for patients with advanced pancreatic cancer, and it may change the 
classical paradigm of gemcitabine as the keystone in the management of advanced 
pancreatic cancer.  
2.3 Gemcitabine-resistant disease 
Once the disease progresses to gemcinatine-based therapy there is no accepted standard 
of care and most patients will not be suitable candidates for further therapy due to clinical 
deterioration. Second-line chemotherapy may be considered, however, in patients who 
maintain good performance status, although efficacy in this setting is questionable. 
Overall, it is estimated that approximately 30% of patients are in good condition 
(including good performance status and adequate organ function) for consideration of 
second-line treatment (Gounaris et al, 2010). A number of trials have been performed 
assessing the efficacy of different antineoplastic agents in this context. Most of the 
published evidence, however, consists of small phase II studies testing a variety of drugs 
in a heterogeneous population.  
Oxaliplatin-fluoropyrimidine doublets are probably the chemotherapy regimens most 
widely evaluated in gemcitabine-resistant disease. Several small phase II studies showed 
some promising activity with different combinations of oxaliplatin and 5FU or capecitabine 
(FOLFOX, OFF, XELOX,..), with median survival (6-7 months) that did not substantially 
differed from that observed in chemotherapy-naïve patients (Tsavaris et al, 2005; Xiong et al, 
2008). These results prompted the development of a phase III study (Charité Onkologie; 
CONKO 003) that aimed to evaluate the efficacy of the OFF regimen (oxaliplatin, 
fluorouracil and folinic acid) compared with best supportive care in gemcitabine-pretreated 
patients. Unfortunately, the control arm was closed after 46 of the planned 165 patients were 
enrolled due to clinician reluctance to enroll in a no-treatment arm (Oettle et al, 2005b). The 
results of this initial cohort, however, showed a substantial improvement in overall survival 
for treated patients (22 vs 10 weeks, p=0.0077). The trial design was then modified to include 
an alternative comparator arm consisting of 5FU plus folinic acid (FF regimen) and 165 
patients were subsequently enrolled. Toxicity was acceptable with few grade 3-4 adverse 
events. Median progression-free survival and overall survival were significantly better in 
the OFF arm (13 vs 9 weeks, p=0.012, and 26 vs 13 weeks, p=0.014, respectively) (Pelzer et al, 
2008). 
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Combining gemcitabine and oxaliplatin (GEMOX) has been another commonly evaluated 
therapeutic schedule. Two small non-controlled trials investigated the efficacy of oxaliplatin 
plus fixed-dose rate gemcitabine in patients who had progressed on single agent 
gemcitabine. Although reported response rates were relevant (21-24% of partial responses), 
toxicity was not negligible, with up to half of the patients developing at least one grade 3 
adverse event (Demols et al, 2006, as cited in Gounaris et al, 2010; Fortune el al, 2009, as 
cited in Gounaris et al, 2010). These results, together with the findings of the phase III E6201 
conducted in chemotherapy-naïve patients failing to demonstrate a survival advantage for 
the combination, do not warrant further evaluation of this regimen in the second-line setting 
(Poplin et al, 2009). 
Irinotecan has been tested both as single agent and in combination with oxaliplatin or 
fluoropyrimidines showing some activity and an acceptable toxicity profile (Yi et al, 2009; 
Cantore et al, 2004). A direct comparison between oxaliplatin- and irinotecan-based 
regimens was made by Hwang and colleagues in a small randomized phase II trial (Hwang 
et al, 2009). Sixty patients were enrolled and randomly allocated to receive FOLFOX 
(oxaliplatin, folinic acid and infusional 5FU) or FOLFIRI.3 (the same folinic acid and 5FU 
schedule combined with irinotecan) after gemcitabine failure. No significant differences were 
observed among study arms neither in PFS (1.4 vs 1.9 months, p>0.05) nor in OS (4 months 
both regimens). In light of these results, both regimens may be reasonable options for second-
line therapy in appropriately selected patients with advanced pancreatic cancer. Other 
irinotecan-based regimens including combinations with raltitrexed (Ulrich-Pur, 2003, as cited 
in Gounaris, 2010), docetaxel (Ko et al, 2008), docetaxel and mitomycin C (Reni et al, 2004) or 
ifosfamide (Cereda et al, 2011) have not achieved positive results in small phase II trials. 
Rubitecan, an orally bioavailable camptothecin derivative, was the subject of the largest 
study conducted in gemcitabine-resistant pancreatic cancer, despite results of an initial 
single arm study were not particularly encouraging (median TTP and OS of 1.9 and 3 
months, respectively). Subsequently, a large phase III study was launched the results of 
which have only been reported in abstract form (Jacobs et al, 2004). Four-hundred and nine 
patients were randomized to receive treatment with rubitecan or physician’s best choice 
(chemotherapy 89%, supportive care only 11%). There were more responses in the rubitecan 
arm (11% vs. 1%) and the difference in median PFS, although clinically modest, reached 
statistical significance (1.9 vs. 1.6 months). There was no significant difference however in 
OS (3.5 vs 3.1 months, respectively).  
Other tested drugs in this setting, such as taxanes or pemetrexed, have not shown 
particularly promising results in small studies (Gounaris et al, 2010; Boeck et al, 2007b; Mazzer 
et al, 2009). Multidrug combinations such as PEFG (cisplatin, epirubicin, 5-FU and 
gemcitabine) (Reni et al, 2008, as cited in Gounaris et al, 2010) or G-FLIP (gemcitabine, 
irinotecan, folinic acid, 5-FU and cisplatin) (Kozuch et al, 2001, as cited in Gounaris, 2010) 
appear to show improved efficacy with impressive median survival of 8.3 and 10.3 months, 
respectively. Selection bias may at least partially explain these outstanding results as reported 
toxicity was rather high, which in any case would limit their use in the general population.  
3. Molecularly targeted therapies  
Pancreatic adenocarcinoma is a malignant disease that results from the successive 
accumulation of gene mutations (Vogelstein & Kinzsler, 2004) evolving from premalignant 
www.intechopen.com
 Pancreatic Cancer – Clinical Management 
 
96
lesions in the ductal epithelium to invasive cancer. These include activating mutations of 
KRAS2 oncogene (90% of pancreatic tumors), and inactivation of the tumor-suppresor genes 
CDKN2A (95%), TP53 (50-75%) or DPC4 (50%). More recent comprehensive genetic analysis 
have shown that molecular features in pancreatic cancer may be extremely complex and 
heterogeneous (Jones et al, 2008), although these genetic abnormalities may be classified in 
12 core cancer signaling pathways involving not only pancreatic cancer cells but also other 
fundamental components of neoplasia such as cancer stem cells and tumor stroma (Hidalgo, 
2010). As molecular pathways governing pancreatic cancer development are unraveled, 
novel targets emerge that may provide some promise to improve the dismal results 
obtained with conventional cytotoxic therapy.  
3.1 EGFR-RAS-MEK-ERK pathway 
EGFR (epidermal growth factor receptor), also known as HER-1 or ErbB-1, is activated by 
several ligands that include EGF (epidermal growth factor), TGF-α (transforming growth 
factor alpha), HB-EGF (heparin-binding EGF), amphiregulin, epiregulin, betacellulin and 
neuregulin. Activated EGFR forms homo- or heterodimeric complexes with other members 
of the ErbB family, triggering downstream signaling pathways such as Ras/MAP kinase, 
phosphatidylinositol 3’-kinase (PI3K)/Akt, Janus kinase (JAK)/Stat and phospholipase 
C/protein kinase C, that ultimately activate genes involved in cell proliferation, migration, 
adhesion, differentiation and apoptosis (Di Marco et al, 2010). Overexpression of EGFR and 
its ligands is very common in pancreatic cancer, and it is linked to increased tumor 
aggressiveness and poor prognosis. Preclinical studies have shown that blocking EGFR 
signaling inhibits growth and metastasis of pancreatic tumors in xenograft models and 
synergistic activity has been documented when combined with gemcitabine (Tempero et al, 
2011). 
Two strategies to antagonize EGFR signaling have been evaluated in the clinic to date: 
inhibition of the tyrosine kinase intracellular domain by small molecules and EGFR 
inhibition by monoclonal antibodies directed against the extracellular ligand binding 
domain. Erlotinib is an oral tyrosine kinase inhibitor [TKI] against EGFR, and the only 
targeted drug that has demonstrated some efficacy in pancreatic cancer thus far. The 
National Cancer Institute of Canada PA.3 trial was a phase III randomized study evaluating 
standard gemcitabine plus erlotinib (100 or 150 mg/day) versus gemcitabine plus placebo in 
569 patients with chemo-naïve advanced pancreatic cancer (Table 2). Both PFS (PFS 3.75 vs 
3.55 months, HR 0.77, p=0.004) and OS (6.24 vs 5.91 months, HR 0.82, p=0.038) were 
significantly improved in the experimental arm (Moore et al, 2007). Most common toxicity 
was, as expected, diarrhea and skin rash, which were of grade 1-2 in the majority of cases 
without negatively impacting patient´s quality of life. Interestingly, patients that developed 
grade 2 or higher skin rash had significantly longer survival compared to those who 
developed mild or no rash (10.5 vs 5.8 vs 5.3 months, respectively, HR 0.74, p=0.037). Levels 
of EGFR expression, however, were not correlated with survival. This was the pivotal study 
that granted erlotinib marketing authorization by regulatory authorities, although the small 
magnitude of benefit has precluded widespread acceptance by oncologists in Europe of the 
gemcitabine-erlotinib combination as the new standard of care for first line therapy of 
advanced pancreatic cancer.  
One potential explanation for this modest effect of EGFR inhibition in pancreatic cancer is 
the fact that KRAS mutations occur in 70-90% of these tumors (Tempero et al, 2011). KRAS 
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Reference Treatment Number 
of patients 
OS 
(months) 
PFS 
(months) 
RR  
(%) 
Moore  
et al (2007) 
GEM + PLA vs 
GEM+ERLOT 
569 5.91 vs 6.24 
(p=0.038) 
3.55 vs 3,.75 
(p=0.004) 
8 vs  
8.6 
Philip  
et al (2007) 
GEM vs 
GEM+CETUX 
766 6 vs 6.5 
(p=0.14) 
3 vs 3.5 
(p=0.058) 
14 vs 
12 
Van 
Cutsem  
et al (2009) 
GEM+ERLOT+PLA 
vs 
GEM+ERLOT+BEV 
607 6 vs 7.1 3.6 vs 4.6 
(p=0.0002) 
8.6 vs 
13.5 
Kindler  
et al (2010) 
GEM+PLA vs 
GEM+BEV 
602 5.9 vs 5.8 
(p=0.95) 
2.9 vs 3.8 
(p=0.07) 
10 vs 
13 
Moore  
et al (2003) 
GEM vs BAY 12-9566 277 6.59 vs 3.74 
(p<0.01) 
3.5 vs 1.68 
(p<0.01) 
- 
Bramhall  
et al (2001) 
GEM vs 
MARIMASTAT 
414 5.5 vs 4.1 3.8 vs 1.9 25.8 vs 
2.8 
Bramhall  
et al (2002) 
GEM vs 
GEM+MARIMASTAT 
239 5.4 vs 5.4 3.1 vs 3 16 vs 
11 
Van 
Cutsem  
et al (2004) 
GEM vs 
GEM+TIPIFARNIB 
688 6 vs 6.3 
(p=0.75) 
3.6 vs 3.7 
(p=0.72) 
8 vs  
6 
GEM, gemcitabine; PLA, placebo; ERLOT, erlotinib; BEV, bevacizumab; RR, response rate; PFS, 
progression free survival; OS, overall survival 
Table 2. Selected phase III trials of targeted agents in advanced pancreatic cancer  
functions downstream of the EGFR signaling pathway, and mutations in the KRAS protein 
lead to constitutive activation independent of extracellular stimuli. This is a well established 
mechanism of resistance to EGFR blockade in colorectal cancer, and, indeed, EGFR-targeted 
therapy is only to be used in KRAS wild-type tumors. The potential predictive value of 
KRAS mutation status and EGFR gene copy number in pancreatic cancer was evaluated in 
26% of the patients included in the PA.3 trial who had tumor samples available for analysis. 
KRAS mutations were detected in 79% of tested samples. EGFR copy number was not 
correlated with treatment effect. However, the HR of death between gemcitabine/erlotinib 
and gemcitabine/placebo was 1.07 for patients with KRAS-mutated tumors versus 0.66 for 
those with KRAS wild-type tumors. Although this difference did not reach statistical 
significance probably due to small numbers, this plausible trend shall be further evaluated 
to try to improve patient selection and therapeutic benefit. 
Erlotinib has also been tested as second-line treatment of patients with advanced disease. 
Kulke et al evaluated the combination of erlotinib and capecitabine in 30 patients with 
gemcitabine-refractory pancreatic cancer. Objective radiologic responses were observed in 
10% of patients and the median survival was 6.5 months. In addition, 17% of treated patients 
experienced decreases in tumor marker (CA 19-9) levels of more than 50% from baseline. 
However, common toxicities, particularly diarrhea and skin rash, were significant and 
required treatment dose reductions in 66% of patients (Kulke et al, 2007). More recently, this 
treatment regimen has been tested against erlotinib-gemcitabine in a phase III AIO trial. This 
trial included 279 chemotherapy naïve patients that were randomly allocated to receive 
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capecitabine-erlotinib versus gemcitabine-erlotinib as the control arm. Crossover to 
gemcitabine or capecitabine alone was allowed at the time of progression. Neither time to 
treatment failure of second-line therapy (TTF2), which was the primary endpoint of the trial, 
nor OS were significantly different among study arms (TTF2 4.4 vs 4.2 months, HR 0.98, 
p=0.43; OS 6.9 vs 6.6 months, HR 0.96, p=0.78). Of note, overall survival was significantly 
correlated with KRAS mutation status (8.0 months vs 6.6 months for KRAS wild-type versus 
mutated tumors, respectively; HR 1.62; p=0.011). However, the study design, which 
included erlotinib in both treatment arms, does not allow to elucidate whether KRAS 
mutation status is predictive of efficacy of EGFR-targeted therapy or just a prognostic factor 
independent of therapy (Boeck et al, 2010). Anyhow, this regimen may represent an 
acceptable treatment option in patients who experience treatment failure with standard 
gemcitabine first-line therapy or for whom gemcitabine may not be an appropriate 
treatment option. 
The other strategy to antagonize EGFR signaling consists of monoclonal antibodies directed 
against the extracellular domain of the receptor, such as cetuximab or panitumumab. They 
are currently approved for treatment of other advanced malignancies such as colorectal or 
head and neck cancer. Preclinical and early clinical trials suggested some efficay too in 
pancreatic cancer. Disappointingly, a large phase III trial comparing the combination of 
cetuximab plus gemcitabine vs gemcitabine alone (Table 2), which enrolled 366 patients, did 
not demonstrate a benefit in survival for the combination regimen (Philip et al, 2007). Other 
approaches explored include dual EGFR inhibition (TKI inhibitors plus monoclonal 
antibodies). Preliminary results of a phase II randomized study suggest a small benefit in 
terms of PFS (3.3 months vs 2.0 months) for the addition of panitumumab to gemcitabine-
erlotinib, although statistical significance was not reported and final data including overall 
survival are awaited for definitive conclusions (Kim et al, 2010). 
Lapatinib, an oral TKI which reversibly inhibits both EGFR/HER1 and HER2/neu, has also 
been evaluated. Preclinical assays suggested activity alone and in combination with other 
drugs such as capecitabine. Moreover, a phase I trial combining lapatinib with either 
gemcitabine or GEMOX showed encouraging results with median survival of 10 months 
(Safran et al, 2008, as cited in Di Marco et al, 2010). More recently, preliminary results of a 
single arm phase II trial evaluating the combination of capecitabine and lapatinib as first-
line treatment in advanced pancreatic cancer have been presented. Survival of 6 months was 
not reached in 7 of the 9 enrolled patients, and none of them obtained objective responses 
(McDermott et al, 2011). This data led to the premature termination of the study. 
HER2 may be also targeted by monoclonal antibodies such as trastuzumab. HER2 is 
overexpressed in some pancreatic cancers, with results widely varying from 0 to 82% in 
different studies. One early trial evaluated gemcitabine plus trastuzumab in 34 metastatic 
pancreatic cancer patients with 2+/3+ Her2-positive tumors determined by 
immunohistochemistry. Only 4 patients (12%) presented Her2 neu 3+ expression. Partial 
responses were observed in 6% of patients (2/32) (Safran et al, 2004). Further studies would 
be needed to appropriately assess the role of this agent in pancreatic cancer. 
Other therapeutic strategies have aimed to target some of the downstream effectors of 
EGFR. The high incidence of KRAS mutations in pancreatic cancer provided a strong 
rationale for the evaluation of KRAS inhibition. Tipifarnib was the first agent of this class to 
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be tested. It is a farnesyl transferase inhibitor which demonstrated antiproliferative activity 
in a wide range of tumors in preclinical models. Farnesylation is an impotant post-
traslational event required for Ras activation. A large phase III clinical trial, however, failed 
to demonstrate an improvement in survival of adding tipifarnib to gemcitabine over 
gemcitabine alone in patients with advanced pancreatic cancer (Table 2) (Van Cutsem et al, 
2004). Some authors have postulated as a potential explanation for these negative results the 
fact that KRAS mutation could be an early event in the development of pancreatic cancer, 
becoming cancer cells less dependent on this pathway as the disease progresses. In addition, 
other mechanisms involved in the regulation of Ras activation (i.e. prenylation by other 
enzymes) may limit the therapeutic success of farnesyl transferase inhibition (Lobell R et al, 
2001, as cited in Stathis & Moore, 2010). 
Other agents targeting downstream effectors of the EGFR pathway currently under 
evaluation include MEK inhibitors. Phase I trials have established the recommended dose 
for further clinical development and have documented rash, diarrhea and central serous 
retinopathy as dose limiting toxicities, all of them reversible (Messersmith et al, 2011). 
Several phase I and II trial combining MEK inhibitors with standard chemotherapy and 
other targeted agents are ongoing, the results of which are awaited with great interest. 
3.2 Antiangiogenic agents 
Angiogenesis is a widely validated target for cancer therapy. Overexpression of vascular 
endothelial growth factor (VEGF) and its receptors (VEGFRs) has been described in 
pancreatic cancer and correlated with disease progression and poor prognosis. Bevacizumab 
is a recombinant humanized anti-VEGF monoclonal antibody and the most widely tested 
antiangiogenic agent. Promising data of several bevacizumab combination regimens in 
phase II clinical trials, with response rates of up to 24% and median survival of up to 11 
months (Kindler et al, 2005; Walkins et al, 2010; Iyer et al, 2008, as cited in Di Marco et al, 
2010), encouraged the development of two large phase III trials that unfortunately failed to 
yield positive results. The first one enrolled 602 patients that were randomized to receive 
gemcitabine plus bevacizumab or gemcitaine plus placebo. No significant differences were 
observed among study arms neither in PFS (PFS 3.8 vs 2.9 months) nor in OS (5.8 vs 5.9 
months) (Kindler et al, 2010). The second one evaluated the addition of bevacizumab to the 
gemcitabine-erlotinib doublet (Table 2). Although PFS was better for the experimental arm 
(4.6 vs 3.6 months, HR 0.73, p=0.0002), the primary objective of the study was not met as the 
addition of bevacizumab did not improve overall survival (7.1 vs 6.0 months, HR 0.89, 
p=0.2) (Van Cutsem et al, 2009). A correlation between development of skin rash and 
improvement in survival was observed in this trial. 
Other broadly tested agents that interfere with angiogenesis include small molecules 
targeting multiple kinases such as axitinib or sorafenib. Axitinib, an oral inhibitor of 
VEGFR-1, VEGFR-2 and VEGFR-3, was initially evaluated in a phase II randomized trial 
in combination with gemcitabine versus gemcitabine alone. This trial enrolled 103 patients 
and showed a small improvement in survival favoring the combination arm (6.9 vs 5.6 
months), although this difference did not reach statistical significance (Spano et al, 2008). 
Nevertheless, a phase III trial was undertaken but was prematurely discontinued due to 
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the lack of benefit observed in an interim analysis for the addition of axitinib to the 
standard gemcitabine therapy. Sorafenib has also been evaluated in combination with 
both gemcitabine and gemcitabine-erlotinib in different non-controlled trials with 
disappointing results (Wallace et al, 2007; Cohen et al, 2011). The lack of success of 
antiangiogenic strategies in pancreatic cancer could be potentially related to the fact that 
most tumors display intense fibrosis and are of hypovascular nature (Stathis & Moore, 
2010).  
3.3 Matrix metalloproteinases (MMP) inhibitors 
MMPs are a family of zinc-dependent proteolytic enzymes implicated in the degradation of 
extracellular matrix proteins both in physiological and pathological conditions. Aberrant 
MMP expression contributes to neovascularization, dissemination and metastasis of a 
variety of solid malignancies (Stathis & Moore, 2010). Several compounds developed to 
inhibit MMPs have been completely unsuccessful in clinical trials over the last decade. 
Marimastat was the first agent to be tested (Table 2). Two large phase III trials enrolling over 
900 patients showed marimastat, either alone or in combination with gemcitabine, was not 
able to improve survival or disease control of patients with advanced pancreatic cancer 
(Bramhall et al, 2001, 2002). Similar negative results were obtained with other agents of this 
class. Standard gemcitabine monotherapy was compared to BAY 12-9566, in a design that 
allowed for crossover after disease progression. Interim analyses demonstrated a deleterious 
effect on survival of the MMP inhibitor as compared to the control arm (OS 3.74 vs 6.59 
months, p<0.01), and led to early trial termination (Moore et al, 2003). In light of this data, 
this approach has been definitively abandoned. 
3.4 Other pathways 
Phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR 
The PI3K/Akt/mTOR pathway is determinant for processes related to cell proliferation and 
inhibition of apoptosis, and constitutive activation of this pathway has been documented in 
pancreatic cancer (Royal et al, 2008). NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor that 
has demonstrated activity in both human pancreatic cancer cell lines and mice models, and 
some synergy has been observed when combined with gemcitabine and antiangiogenic 
EMAP II (endothelial monocyte activating polypeptide II) (Awasthi et al, 2011). Further 
research will define the role of these new drugs in pancreatic cancer. 
Src kinase 
Src tyrosine kinase is a non-receptor protein implicated in tumor progression. It is 
overexpressed in more than two thirds of pancreatic adenocarcinomas. Src inhibitors 
(dasatinib, saracatinib) have been developed demonstrating antitumor activity in cancer cell 
lines and mice models (Royal et al, 2008). A recent phase II trial tested saracatinib 
(AZD0530) in 19 gemcitabine-refractory patients. No responses were seen and the minimum 
of 18% 6-month survival required for continuation of the trial was not achieved. A 
pharmacodiagnostic pre-selection strategy is planned to be implemented to better define 
patients most likely to respond (Nallapareddy et al, 2010).  
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IGF-1R 
IGF-1R mediated signaling plays an important role in cell growth regulation and survival. 
Several monoclonal antibodies targeting IGF-IR have undergone clinical investigation 
(AMG479, MK0646, R1507). Based on promising preclinical and early clinical data, a phase 
III trial has been initiated to evaluate the combination of AMG479 plus gemcitabine in first-
line metastatic pancreatic cancer (Hidalgo, 2010). 
TNF-α 
TNF-α shows potent anticancer activity, but high systemic toxicity limits its use. 
AdEgr.TNF.11D (TNFerade) is a gene delivery strategy to increase local peritumoral TNF 
concentrations through intratumoral injections of an adenoviral vector expressing hTNF, in 
an attempt to improve local activity while minimizing systemic effects. Effectiveness in 
combination with gemcitabine has been demonstrated in human pancreatic xenografts 
(Murugesan et al, 2009). A phase III trial is currently evaluating the addition of TNFerade to 
5-FU plus radiotherapy in unresectable pancreatic cancer (Stathis & Moore, 2010). 
Multikinase inhibitor 
Masitinib is a multikinase inhibitor that has greater activity and selectivity against KIT 
than imatinib. Masitinib also potently inhibits PDGFR (platelet-derived growth factor 
receptor) and the intracellular kinase Lyn, and to a lesser extent, FGFR3 (fibroblast growth 
factor receptor 3). Synergistic activity with gemcitabine was demonstrated in preclinical 
assays. A phase II trial combining gemcitabine and masitinib in 22 patients reported 
median PFS of 6.4 months and OS of 7.1 months, with a 23% 18-months survival rate. 
Toxicity was acceptable, being cytopenia, diarrhea and rash the most common severe 
events (Hammel et al, 2009). A subsequent phase III trial is ongoing comparing 
gemcitabine with or without masitinib. 
Death receptors 
AMG655 is a monoclonal antibody against human death receptor 5 (DR5) that activates 
caspases and, as a result, induces apoptosis in tumor cells. It showed preclinical activity and 
synergy with gemcitabine. Early clinical data from a phase I trial that included 13 patients 
reported promising results for the combination of AMG655 with gemcitabine, with a 
response rate of 31%, median PFS of 5.3 months and a 6-month survival rate of 76.8%. 
Toxicity was however not negligible, with severe adverse events observed in 69% of patients 
(Kindler et al, 2009). A phase II is ongoing to assess efficacy and further characterize the 
safety profile of this combination.  
Other pathways 
Other pathways highly implicated in pancreatic tumorigenesis are at earlier stages of 
investigation. Hedgehog, Notch and Wnt signaling are important developmental pathways 
related to pancreatic cancer stem cells, and new agents are being developed to target these 
pathways (GDC-0449, IPI-926,..). Other agents in development include monoclonal 
antibodies against cell-membrane proteins such as mesothelin (MORAb-009). Specific 
mechanisms of cell killing are still not well defined but preclinical research suggest a role in 
pancreatic cancer (Hidalgo, 2010). 
www.intechopen.com
 Pancreatic Cancer – Clinical Management 
 
102 
4. Conclusions 
Pancreatic cancer continues to be a major challenge for oncologists as it is a highly 
chemoresistant malignancy carrying an extremely poor prognosis. Despite the intense 
research carried out over the last decades no major improvements have been achieved in 
patient’s outcomes. Most patients present with locally advanced or metastatic disease and 
will therefore require systemic therapy. Conventional chemotherapy modestly improves 
survival and quality of life of patients with advanced disease. Gemcitabine has been the 
reference treatment for over a decade and little progress has been made since its 
introduction in clinical practice in 1997. Gemcitabine-combination therapy with 
capecitabine, platinum agents or erlotinib may be considered in patients with good 
performance status, although the small magnitude of benefit they confer shall be balanced 
against the increased toxicity they induce, particularly considering that prognosis is in any 
case rather poor and symptomatic relief shall be a major objective of disease management. 
FOLFIRINOX may be a preferred option for carefully selected fit patients, particularly those 
with locally advanced borderline resectable disease.  
Nevertheless, there is much room for improvement, and more efforts in basic, translational 
and clinical research will be necessary in the following years for progress to be made. 
Indeed, a better understanding of the biology of pancreatic cancer shall enable the discovery 
of new targets of potential diagnostic or therapeutic interest. Meanwhile, as the molecular 
pathways governing pancreatic cancer are unraveled, efforts shall be made to improve 
selection of patients most likely to benefit from specific therapies (SPARC, kras,..). Small 
randomized phase II trials of both non-selected and enriched patient populations will help 
to adequately identify potentially active new agents. Phase III trials should only be initiated 
in appropriate patients based on strong clinical and biological grounds. In this context, the 
need for further collaborative research is highly warranted. 
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